EMA Accepts AstraZeneca’s Naloxegol Application

mia.burns Marketing Authorisation Application for naloxegol accepted by European Medicines Agency Friday, 27 September 2013 AstraZeneca today announced that the European Medicines ...

Relypsa pitches $126M IPO as lead CKD drug nears moment of PhIII truth

John Carroll Just weeks away from reporting key endpoint data from a Phase III trial of its lead therapy, Relypsa has mapped out plans to go public, shooting for a $ 126.5 million ...

Achillion shares crushed in a rout as hep C blockbuster hopes fade

John Carroll After the market closed on Friday, Achillion spread the word that the FDA is maintaining its clinical hold related to its once-hot hepatitis C drug sovaprevir, while distributing ...

Pharmalot… Pharmalittle… The Weekend Nears

esilverman And so, another working week is about to draw to a close. Hard to believe, yes? Well, as you know, this is our treasured signal to daydream about weekend plans. ...

Dainippon Submits Antipsychotic Approval Application in China

mia.burns Dainippon Sumitomo Pharma submits an application for an atypical antipsychotic blonanserin (Brand name in Japan: LONASEN®) in China Osaka, Japan, September 27, 2013 – ...

Roche’s new round of lung cancer data keeps spotlight on immunotherapies

John Carroll FierceBiotech News

Up And Down The Ladder… Job Changes

esilverman Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s ...

Eli Lilly’s diabetes strategy doesn’t include big staff-up in sales

Tracy Staton As Lilly Diabetes President Enrique Conterno tells Bloomberg, the company plans to lean on its broad product portfolio to grow sales, rather than sending out legions of ...

Lilly Announces Positive Type 2 Diabetes Data

mia.burns Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly’s Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes Improvements ...

Cost gatekeepers give final ‘no’ to Pfizer’s targeted cancer drug Xalkori

Tracy Staton Clinically effective but not cost-effective. That's what U.K. watchdogs have determined about Pfizer's targeted lung cancer drug, Xalkori. Despite a discount offer ...

Forget The Apology: Japan To Raid Novartis Offices Over Diovan Scandal

esilverman Japanese authorities plan to raid Novartis offices after a health ministry panel concluded that the drugmaker should be held responsible for using falsified research ...

Merck KGaA overhauls pharma management to boost growth

Tracy Staton Merck KGaA is rejigging its pharmaceuticals management, promoting pharma chief Stefan Oschmann to a new job overseeing prescription and consumer drugs, biosimilars and ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS